BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 07, 2006
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 2Q06 EPS est 2Q06 EPS actual Outcome Growth from 2Q05 8/4 cls Wk chg % chg Mcap hg 8/4 Mcap
Affymetrix (AFFX) -$0.01 -$0.09 Missed by $0.08 NA $20.03 -$2.23 -10% -$150.1 $1,348.3
The $0.09 loss per share includes a tax charge of $0.08 per share. AFFX also missed the Street's top line expectations, posting 2Q06 revenues of $80.1M vs. the consensus estimate of $88.8M. The microarray company attributed the revenue decline to increased competition, especially in the genotyping market, and said it plans to improve profitability by offering more products and reducing operating costs. AFFX reported EPS of $0.12 in 2Q05.
BioMarin (BMRN) -$0.11 -$0.02 Beat by $0.09 NA $15.61 $0.82 6% $70.2 $1,335.5
BMRN reported a loss per share of $0.33 in 2Q05. 2Q06 sales of Naglazyme, which was approved in 2Q05 to treat mucopolysaccharidosis VI (MPS-VI, Maroteaux-Lamy syndrome), were $10.3M. Also, BMRN and partner Genzyme (GENZ) reported $23.5M in 2Q06 sales of Aldurazyme for MPS-I (Hurler's syndrome), up 23% from $19.2M in 2Q05. BMRN raised its full-year sales guidance for Naglazyme to $40-$44M from $31-$34M and...

Read the full 1064 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >